Status:

COMPLETED

Nordic Study on the Effects of Growth Hormone (Norditropin SimpleXx) Treatment in Adults With Prader-Willi Syndrome

Lead Sponsor:

Karolinska University Hospital

Collaborating Sponsors:

Novo Nordisk A/S

Conditions:

Prader-Willi Syndrome

Eligibility:

All Genders

18-50 years

Phase:

NA

Brief Summary

The aim of this study is to study the effects of GH on body composition, lipid and glucose metabolism, physical performance and safety aspects in adults with PWS.The patients are randomized to either ...

Detailed Description

OBJECTIVE(S): Prader Willi syndrome (PWS) is a multi-symptomatic genetic disorder associated with abnormalities in the growth hormone (GH)-insulin-like-growth factor (IGF)-I axis and in the body comp...

Eligibility Criteria

Inclusion

  • Genetically verified PWS diagnosis (by methylation and FISH test.)
  • Between 18 and 50 years old
  • Informed consent obtained before any trial-related activities. (Trial-related activities are any procedure that would not have been performed during normal management of the treatment of the subject.)

Exclusion

  • Known or suspected allergy to GH preparation.
  • Previous participation in this trial.
  • GH treatment within the last 1 years
  • Malignancy or other serious diseases (ex severe cardiovascular diseases, severe infections)
  • Sexhormone treatment initiated within the last year
  • Pregnancy
  • Untreated respiratory impairment, untreated sleep apnoea or untreated respiratory infection.

Key Trial Info

Start Date :

April 1 2005

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 1 2010

Estimated Enrollment :

46 Patients enrolled

Trial Details

Trial ID

NCT00372125

Start Date

April 1 2005

End Date

March 1 2010

Last Update

September 13 2016

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

Center for rare Diseases, Department of Pediatrics, Skejby University Hospital

Aarhus N, Denmark, 8200

2

Endokrinologisk seksjon, Med Avd, Rikshospitalet

Oslo, Norway

3

Department of Endocrinology and Diabetology, Karolinska Hospital

Stockholm, Sweden, 171 76